Home›Ceritinib

Ceritinib

Kinase InhibitorTyrosine Kinase InhibitorsCytochrome P450 3A Inhibitors

Route: Oral

8 interactions on record

Ceritinib has 8 known drug interactions based on U.S. FDA drug labeling data. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Grapefruit Products, Ketoconazole, Nirmatrelvir And Ritonavir. Patients taking Ceritinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 8
Major: 6
Moderate: 1

Major (6)

Ceritinib + Grapefruit Products— Grapefruit may inhibit CYP3A and increase ceritinib exposure. Do not consume grapefruit or grapefruit juice during treat…
Ceritinib + Ketoconazole— Strong CYP3A4/P-gp inhibitor increased systemic exposure of ceritinib, which may increase incidence and severity of adve…
Ceritinib + Nirmatrelvir And Ritonavir— Anticancer drugs abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax…
Ceritinib + Rifampin— Strong CYP3A4/P-gp inducer decreased systemic exposure of ceritinib, which may decrease efficacy of ZYKADIA. Avoid concu…
Ceritinib + Voriconazole— Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabr…
Ceritinib + Warfarin— Ceritinib increased systemic exposure of warfarin, enhancing anti-coagulant effect. Increase INR monitoring frequency if…

Moderate (1)

Ceritinib + Midazolam— Ceritinib increased systemic exposure of this sensitive CYP3A substrate. Avoid coadministration or consider dose reducti…

Ceritinib + Grapefruit Products⚠️Major

Grapefruit may inhibit CYP3A and increase ceritinib exposure. Do not consume grapefruit or grapefruit juice during treatment.

Ceritinib + Ketoconazole⚠️Major

Strong CYP3A4/P-gp inhibitor increased systemic exposure of ceritinib, which may increase incidence and severity of adverse reactions. Avoid concurrent use or reduce ZYKADIA dose if unavoidable.

Ceritinib + Nirmatrelvir And Ritonavir⚠️Major

Anticancer drugs abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer drugs Avoid co-administration of encorafenib or ivosidenib due to potential risk of serious adverse events such as QT interval prolongation.

Ceritinib + Rifampin⚠️Major

Strong CYP3A4/P-gp inducer decreased systemic exposure of ceritinib, which may decrease efficacy of ZYKADIA. Avoid concurrent use.

Ceritinib + Voriconazole⚠️Major

Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of VFEND.

Ceritinib + Warfarin⚠️Major

Ceritinib increased systemic exposure of warfarin, enhancing anti-coagulant effect. Increase INR monitoring frequency if coadministration unavoidable; consider dose reduction.

Ceritinib + Midazolam🟡Moderate

Ceritinib increased systemic exposure of this sensitive CYP3A substrate. Avoid coadministration or consider dose reduction of midazolam if unavoidable.

Ceritinib + Itraconazoleℹ️Unknown

Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib a Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olapariba Pazopanib Sunitinib Trabectedin Trastuzumab emtansine Vinca alkaloids Not recommended during and 2 weeks after itraconazole treatment.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.